Get the Stockscreener App
4.12
3.78%
0.15
Pre-market:
4.11
-0.010
-0.24%
Chimerix Inc Stock (CMRX) Latest News
Its Stock Has Paid Off Big Time For Chimerix Inc - SETE News
CMRX stock rated an Outperform by Robert W. Baird - Knox Daily
Market Highlights: Chimerix Inc (CMRX) Ends on a Low Note at 3.80 - The Dwinnex
Chimerix (NASDAQ:CMRX) Shares Cross Above 200-Day Moving AverageHere's What Happened - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) VP Sells $11,480.00 in Stock - MarketBeat
Chimerix stock soars to 52-week high, hits $4.22 - MSN
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know - Yahoo Finance
Chimerix stock soars to 52-week high, hits $4.22 By Investing.com - Investing.com UK
Chimerix (NASDAQ:CMRX) Share Price Passes Above Two Hundred Day Moving Average – Here’s Why - Defense World
Chimerix Leadership Reveals Future Growth Strategy at Elite Healthcare Conference - StockTitan
Chimerix Grants Stock Options to New Employees, Advances Drug Development - StockTitan
Chimerix stock soars to 52-week high, hits $3.8 - MSN
Chimerix stock soars to 52-week high, hits $3.8 By Investing.com - Investing.com Australia
Assenagon Asset Management S.A. Purchases 496,823 Shares of Chimerix, Inc. (NASDAQ:CMRX) - MarketBeat
Assenagon Asset Management S.A. Has $2.85 Million Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Here’s Why Chimerix, Inc. (CMRX) Is Skyrocketing - MSN
Chimerix, Inc. (NASDAQ:CMRX) Sees Large Decline in Short Interest - MarketBeat
Why These 24 Stocks Are Skyrocketing - Insider Monkey
Chimerix to Speak Today at The White House Cancer Moonshot Forum - The Manila Times
Chimerix CSO to Present at Biden Cancer Moonshot Forum on Breakthrough Brain Cancer Treatment - StockTitan
Geode Capital Management LLC Trims Holdings in Chimerix, Inc. (NASDAQ:CMRX) - Defense World
Chimerix stock soars to 52-week high, hits $3.73 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Shares Pass Above 50-Day Moving AverageHere's What Happened - MarketBeat
Chimerix stock soars to 52-week high, hits $3.73 - Investing.com
Chimerix asks FDA to approve oral dordaviprone as glioma treatment - Myeloma Research News
H.C. Wainwright reiterates Buy rating on Chimerix stock amid NDA submission for ONC201 - Investing.com Canada
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 - Investing.com Australia
Buy rating reaffirmed on Chimerix stock with potential 3Q25 launch for ONC201 By Investing.com - Investing.com South Africa
Chimerix (NASDAQ:CMRX) Given Buy Rating at HC Wainwright - Defense World
Chimerix (NASDAQ: CMRX) Enters Amended Loan Agreement with Silicon Valley Bank - Defense World
Chimerix takes pivotal step for novel brain cancer drug - The Business Journals
A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts - Benzinga
Chimerix's (CMRX) "Buy" Rating Reaffirmed at HC Wainwright - MarketBeat
Chimerix, Inc. Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - Marketscreener.com
Chimerix (CMRX) Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse Glioma - StreetInsider.com
Chimerix Files FDA Application for Novel Brain Cancer Drug Dordaviprone, Secures $30M Launch Funding - StockTitan
Chimerix stock soars to 52-week high, hits $3.44 By Investing.com - Investing.com Nigeria
Chimerix stock soars to 52-week high, hits $3.44 - Investing.com India
Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update - MarketBeat
Chimerix, Inc. (NASDAQ:CMRX) Sees Significant Drop in Short Interest - MarketBeat
Biodefense Market CAGR of 7.3% Size, Growth Drivers and Forecast 2024-2031 | XOMA corporation, Altimmune Inc., - EIN News
Wedbush Weighs in on Chimerix’s Q4 Earnings (NASDAQ:CMRX) - Defense World
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):